ArticleFrontiers in immunology2025
Association between SARS-CoV-2 infection and anti-apolipoprotein A-1 antibody in children.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Autoantibodies against apolipoprotein A-1 (AAA1) are elicited by SARS-CoV-2 infection and predict COVID-19 symptoms persistence at one year in adults, but whether this applies to children is unknown. We studied the association of SARS-CoV-2 exposure with AAA1 prevalence in children and the association of AAA1 seropositivity with symptom persistence. Methods: Anti-SARS-CoV-2 and AAA1 serologies were examined in 1031 participants aged 6 months to 17 years old from the prospective SEROCOV-KIDS cohort and recruited between 12.2021 and 02.2022. Four SARS-CoV-2 serology-based groups were defined: "Infected-unvaccinated (I+/V-)", "Uninfected-vaccinated (I-/V+)", "Infected-Vaccinated (I+/V+)", and "Naïve (I-/V-)". Reported outcomes were collected using online questionnaires. Associations with study endpoints were assessed using logistic regression. Results: Overall, seropositivity rates for anti-RBD, anti-N, and AAA1 were 71% (736/1031), 55% (568/1031), and 5.8% (60/1031), respectively. AAA1 showed an inverse association with age but not with any other characteristics. The I+/V- group displayed higher median AAA1 levels and seropositivity (7.9%) compared to the other groups (p ≤ 0.011), translating into a 2-fold increased AAA1 seroconversion risk (Odds ratio [OR]: 2.11, [95% Confidence Interval (CI)]: 1.22-3.65; p=0.008), unchanged after adjustment for age and sex. AAA1 seropositivity was independently associated with a 2-fold odds of symptoms persistence at ≥ 4 weeks (p ≤ 0.03) in the entire dataset and infected individuals, but not ≥ 12 weeks. Conclusions: Despite the limitations of the study (cross-sectional design, patient-related outcomes using validated questionnaires), the results indicate that SARS-CoV-2 infection could elicit an AAA1 response in children, which could be independently associated with short-time symptoms persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.